4-(5-nitro-1H-indol-3-yl)cyclohex-3-enone | 915037-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-(5-nitro-1H-indol-3-yl)cyclohex-3-enone
• 英文别名: 4-(5-nitro-1H-indol-3-yl)cyclohex-3-en-1-one
• CAS: 915037-54-6
• 化学式: C₁₄H₁₂N₂O₃
• 分子量: 256.261
• InChiKey: IOTUSUVEITWNRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  78.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(5-nitro-1H-indol-3-yl)cyclohex-3-enone 在 镍 三乙酰氧基硼氢化钠 、 溶剂黄146 、 肼 作用下， 以 甲醇 、 水 、 1,2-二氯乙烷 为溶剂， 反应 14.08h， 生成 3-(4-(dimethylamino)cyclohex-1-enyl)-1H-indol-5-amine
  参考文献：
  名称：

  3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY

  摘要：

  本发明涉及具有一氧化氮合酶（NOS）抑制活性以及对去甲肾上腺素转运蛋白（NET）具有抑制活性的新型3,5-取代吲哚化合物（I）的公式，以及含有它们的药用和诊断组合物，以及它们的医疗用途。

  公开号：

  US20090131503A1
• 作为产物：
  描述：

  5-硝基吲哚 在 盐酸 、 氢氧化钾 、 水 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 42.17h， 生成 4-(5-nitro-1H-indol-3-yl)cyclohex-3-enone
  参考文献：
  名称：

  3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY

  摘要：

  本发明涉及具有一氧化氮合酶（NOS）抑制活性以及对去甲肾上腺素转运蛋白（NET）具有抑制活性的新型3,5-取代吲哚化合物（I）的公式，以及含有它们的药用和诊断组合物，以及它们的医疗用途。

  公开号：

  US20090131503A1

文献信息

• Substituted indole compounds having NOS inhibitory activity
  申请人：Maddaford Shawn

  公开号：US20060258721A1

  公开（公告）日：2006-11-16

  The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

  本发明涉及一种一氧化氮合酶（NOS）的抑制剂，特别是那些选择性地抑制神经型一氧化氮合酶（nNOS）而不是其他NOS同工酶的抑制剂。本发明的NOS抑制剂，单独或与其他药用活性剂结合使用，可用于治疗或预防诸如中风、再灌注损伤、神经退行性疾病、头部创伤、冠状动脉搭桥术（CABG）、伴或不伴有先兆的偏头痛、伴有疼痛性过敏的偏头痛、中枢性中风后疼痛（CPSP）、神经痛、吗啡/阿片类药物引起的耐受性和过度疼痛等疾病。
• SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY
  申请人：Maddaford Shawn

  公开号：US20080249302A1

  公开（公告）日：2008-10-09

  The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.

  本发明涉及一种一氧化氮合酶（NOS）抑制剂，特别是那些选择性地抑制神经元一氧化氮合酶（nNOS）而不是其他NOS亚型。本发明的NOS抑制剂，单独或与其他药理活性剂联合使用，可用于治疗或预防诸如中风、再灌注损伤、神经退行性疾病、头部创伤、CABG、偏头痛（有和无先兆）、伴有痛觉过敏的偏头痛、中枢后中风疼痛（CPSP）、神经病性疼痛、吗啡/阿片类药物引起的耐受和高敏感性等疾病。
• First-in-Class, Dual-Action, 3,5-Disubstituted Indole Derivatives Having Human Nitric Oxide Synthase (nNOS) and Norepinephrine Reuptake Inhibitory (NERI) Activity for the Treatment of Neuropathic Pain
  作者：Gabriela Mladenova、Subhash C. Annedi、Jailall Ramnauth、Shawn P. Maddaford、Suman Rakhit、John S. Andrews、Dongqin Zhang、Frank Porreca

  DOI：10.1021/jm300138g

  日期：2012.4.12

  A family of different 3,5-disubstituted indole derivatives having 6-membered rings were designed, synthesized, and demonstrated inhibition of human nitric oxide synthase (NOS) with norepinephrine reuptake inhibitory activity (NERO. The structure-activity relationship (SAR) within the cyclohexane ring showed the cis-isomers to be more potent for neuronal NOS and selective over endothelial NOS compared to their trans-counterparts. Compounds, such as cis-(+)-37, exhibited dual nNOS and NET inhibition (IC50 of 0.56 and 1.0 mu M, respectively) and excellent selectivity (88-fold and 12-fold) over eNOS and iNOS, respectively. The lead compound (cis-(+)-37) showed lack of any direct vasoconstriction or inhibition of ACh-mediated vasorelaxation in isolated human coronary arteries. Additionally, cis-(+)-37 was effective at reversing both allodynia and thermal hyperalgesia in a standard Chung (spinal nerve ligation) rat neuropathic pain model. Overall, the data suggest that cis-(+)-37 is a promising dual action development candidate having therapeutic potential for the treatment of neuropathic pain.
• 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY
  申请人：Neuraxon, INC.

  公开号：EP2220074A1

  公开（公告）日：2010-08-25
• US7375219B2
  申请人：——

  公开号：US7375219B2

  公开（公告）日：2008-05-20